Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

U. Gatzemeier, A Płużańska, A. Szczęsna, +6

Journal of Clinical Oncology

Advanced NsclcOncologyMedicineCancer ManagementChemotherapy +12

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

U. Gatzemeier, Adi Heller, Dorothee Foernzler, +5

Journal of Clinical Oncology

PathologyChemotherapy +/- ErlotinibTumor BiologyOncologyIhc Analysis +15

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts

Andréas Mackensen, Hendrik Veelken, Michael Lahn, +9

Journal of Molecular Medicine

Tumor ImmunologyCancer ImmunosurveillanceAutoimmune DiseaseInterleukin-2 GeneT-regulatory Cell +9

Palmar fibromatosis (Dupuytren's contracture)

Hiroshi Iwasaki, Harald E. M�ller, U. Brennscheidt

Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin

FibrosisSurgical PathologyHistopathologyPalmar FibromatosisPathology +4

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients

Eric Van Cutsem, Chris Verslype, Philip Beale, +7

Annals of Oncology

Gastrointestinal OncologyMedicinePharmacologyColorectal CancerCancer Treatment +3

Mechanisms of p53 alteration in acute leukemias.

Arndt Schottelius, U. Brennscheidt, Ludwig Wd, +3

PubMed

Molecular Organization of the Human Raf-1 Promoter Region

Thomas W. Beck, U. Brennscheidt, Gunamani Sithanandam, +2

Molecular and Cellular Biology

Transcriptional RegulationNatural SciencesGeneticsTranscription RegulationGene Structure +12

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

Axel‐R. Hanauske, Jim Cassidy, Javier Sastre, +7

Clinical Cancer Research

Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9.

U. Brennscheidt, D. Riedel, Walter Kölch, +5

PubMed

Mitogenic ResponseHematological MalignancyNecessary ComponentMo7 CellsInterleukin 9 +12

A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients

J.P. Delord, Philip Beale, Eric Van Cutsem, +7

Journal of Clinical Oncology

Crc PatientsPathologyPharmacotherapyG4 DiarrheaPre-clinical Pharmacology +20